Page last updated: 2024-08-23

ursodeoxycholic acid and Carcinoma, Hepatocellular

ursodeoxycholic acid has been researched along with Carcinoma, Hepatocellular in 50 studies

Research

Studies (50)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (8.00)18.2507
2000's17 (34.00)29.6817
2010's22 (44.00)24.3611
2020's7 (14.00)2.80

Authors

AuthorsStudies
Arias, IM; Fantappié, O; Gatmaitan, Z; Gentilini, P; Kamimoto, Y; Mazzanti, R1
Hummel-Eisenbeiss, J; Jedlitschky, G; Keppler, D; Nies, AT; Rius, M1
Chen, L; Huang, Z; Kaufman, DL; Kong, X; Lan, E; Peng, S; Tian, J; Zhang, Y1
Abrahamyan, L; Aziz, B; Cheung, A; Flemming, JA; Grbic, D; Gulamhusein, AF; Hansen, BE; Hirschfield, GM; Janssen, HLA; Ko, HH; Lytvyak, E; Mason, AL; Montano-Loza, AJ; Peltekian, K; Qumosani, K; Roberts, SB; Selzner, N; Swain, M; Tirona, K; Vincent, C; Worobetz, LJ1
Ferreira, RD; John, BV; Sy, AM1
Deng, YN; Guh, JH; Hsu, LC; Hsu, YF; Huang, TE; Kung, FL; Marchesi, E; Marchetti, P; Navacchia, ML; Perrone, D1
El-Serag, HB; Emologu, K; Kanwal, F; Natarajan, Y; Patel, P; Qureshi, Z; Shukla, R; Tansel, A; Thrift, AP1
Tanaka, A1
Aitchenson, G; Dahman, B; Deng, Y; Goldberg, DS; John, BV; Kaplan, DE; Khakoo, NS; Levy, C; Martin, P; Schwartz, KB; Taddei, TH1
Barbier, O; Cieślak, A; Gobeil, S; Perreault, M; Thérien, A; Trottier, J; Verreault, M; Vohl, MC1
Bae, JS; Cha, JY; Hahm, KB; Han, YM; Ko, KH; Lee, HJ; Oh, BC; Park, JM1
Parés, A; Reig, A; Sesé, P1
Cho, EJ; Cho, YY; Kim, YJ; Lee, JH; Lee, S; Yoon, JH; Yu, SJ1
Genda, T1
Chen, D; Li, Y; Liu, YJ; Shan, LJ; Xiao, XG; Zhu, L1
Chen, H; Ding, R; Lin, T; Luo, Q; Sun, C; Wang, G; Xu, Y; Zeng, D; Zeng, Z; Zhang, XK1
Battezzati, PM; Burroughs, AK; Caballeria, L; Corpechot, C; Floreani, A; Hansen, BE; Hirschfield, GM; Invernizzi, P; Janssen, HL; Kowdley, KV; Lammers, WJ; Lindor, KD; Lleo, A; Mason, AL; Mayo, MJ; Nevens, F; Parés, A; Ponsioen, CY; Poupon, R; Trivedi, PJ; van Buuren, HR1
Liu, J; Liu, P; Wang, X; Wu, D; Yin, Z; Zhao, Y; Zhou, J1
Matsumura, H; Matsuoka, S; Moriyama, M; Nakamura, H; Nirei, K1
Han, GQ; Huang, Y; Liang, TJ; Liu, H; Qin, CK; Qin, CY; Wei, LL; Xu, HW; Zhang, YZ1
Bruno, S; Carbone, M; Invernizzi, P; Mells, GF; Ronca, V1
Chang, Y; Cho, E; Cho, H; Cho, Y; Cho, YY; Kim, HY; Kim, JE; Kim, YJ; Lee, DH; Lee, JH; Lee, M; Nam, JY; Yoo, JJ; Yoon, JH; Yu, SJ1
Abel, T; Fehér, J1
Fickert, P; Halilbasic, E; Moustafa, T; Trauner, M1
Cullen, S; Maggs, J1
Krok, KL; Munoz, SJ1
Choi, JE; Han, SI; Kang, HS; Lim, SC; Si, H1
Chazouillères, O; Chrétien, Y; Corphechot, C; Garioud, A; Poupon, R; Poupon, RE; Seksik, P1
Batistakis, AG; Drygiannakis, I; Kolios, G; Kouroumalis, EA; Tsagarakis, NJ1
Beuers, U; Denk, GU; Ferdinandusse, S; Fickert, P; Fuchsbichler, A; Hofmann, AF; Invernizzi, P; Kulik, W; Maitz, S; Rust, C; Trauner, M; Wimmer, R1
Gonzalez-Buitrago, JM; Gonzalez-Loyola, A; Gonzalez-Sanchez, E; Marin, JJ; Perez, MJ1
Adang, RP; Brouwer, HT; Drenth, JP; Hansen, BE; Kuiper, EM; Kuyvenhoven, JP; Spoelstra, P; Timmer, R; van Buuren, HR; van Nieuwkerk, CM1
Chung, GE; Kim, HY; Kim, YJ; Lee, HS; Lee, JH; Lee, SH; Lee, SM; Myung, SJ; Yoon, JH; Yu, SJ1
Hino-Arinaga, T; Hisamochi, A; Ide, T; Kuromatsu, R; Kuwahara, R; Miyajima, I; Ogata, K; Sata, M; Torimura, T1
Hirayama, T; Honda, A; Ikegami, T; Imawari, M; Iwamoto, J; Matsuzaki, Y; Miyazaki, T; Nakamuta, M; Saito, Y; Takikawa, H1
Kotb, MA1
Chung, CC; Khaoustov, VI; Krishnan, B; Sohn, J; Xie, Q; Yoffe, B1
Dominguez, M; Garcia-Monzon, C; Larena, MG; Macias, RI; Marin, JJ; Martinez-Diez, MC; Romero, MR; Serrano, MA1
Yamada, G1
Fujiyama, S; Hirokawa, S; Masaki, T; Miyakawa, K; Ohkawa, S; Tamai, S; Tanaka, K; Tarao, K1
Bouscarel, B; Fukushima, S; Ikegami, T; Matsuzaki, Y; Olivier, JL; Shoda, J; Tanaka, N1
Ikeda, H; Iwasaki, Y; Kobashi, H; Makino, Y; Miyake, Y; Okamaoto, R; Sakaguchi, K; Shiratori, Y; Takaguchi, K; Terada, R1
Han, GQ; Liu, H; Meng, M; Qin, CY; Xu, HW; Yang, Z1
Hirano, F; Makino, I; Makino, Y; Okamoto, K; Tanaka, H1
Kato, Y; Khan, KN; Nagataki, S; Nakao, K; Nakata, K; Tsutsumi, T1
Kasahara, A1
Criado, JM; de La Fuente, A; Dominguez, MF; Izco-Basurko, I; Macias, RI; Marin, JJ; Monte, MJ; Pascual, MJ; Yajeya, J1
Eguchi, K; Hamasaki, K; Ichikawa, T; Ida, H; Kajiya, Y; Kato, Y; Kawakami, A; Nakao, K; Nakata, K; Shigeno, M; Takeda, Y1
Tarao, K1
Makino, I; Tanaka, H1

Reviews

12 review(s) available for ursodeoxycholic acid and Carcinoma, Hepatocellular

ArticleYear
Hepatocellular Carcinoma in Primary Biliary Cholangitis.
    Clinics in liver disease, 2022, Volume: 26, Issue:4

    Topics: Carcinoma, Hepatocellular; Cholagogues and Choleretics; Cholangitis; Humans; Liver Cirrhosis, Biliary; Liver Neoplasms; Male; Ursodeoxycholic Acid

2022
Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis.
    Digestive diseases and sciences, 2021, Volume: 66, Issue:7

    Topics: Carcinoma, Hepatocellular; Cholagogues and Choleretics; Humans; Liver Cirrhosis, Biliary; Liver Neoplasms; Ursodeoxycholic Acid

2021
Current understanding of primary biliary cholangitis.
    Clinical and molecular hepatology, 2021, Volume: 27, Issue:1

    Topics: Carcinoma, Hepatocellular; Cholestasis; Humans; Liver Cirrhosis, Biliary; Liver Neoplasms; Ursodeoxycholic Acid

2021
Emerging Targets to Relieve Fat Stress-Induced Liver Diseases: UDCA, Tocotrienol, ω-3 PUFAs, and IgY Targeted NPC1L1 Cholesterol Transporter.
    Current pharmaceutical design, 2017, Volume: 23, Issue:27

    Topics: Animals; Carcinoma, Hepatocellular; Drug Design; Fatty Acids, Omega-3; Humans; Immunoglobulins; Liver Cirrhosis; Liver Neoplasms; Membrane Proteins; Membrane Transport Proteins; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; Tocotrienols; Ursodeoxycholic Acid

2017
Toward precision medicine in primary biliary cholangitis.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2016, Volume: 48, Issue:8

    Topics: Carcinoma, Hepatocellular; Cholagogues and Choleretics; Cholangitis; Clinical Trials as Topic; Disease Progression; Elasticity Imaging Techniques; Humans; Liver Cirrhosis, Biliary; Liver Neoplasms; Precision Medicine; Ursodeoxycholic Acid

2016
[Non-alcoholic fatty liver disease and cardiovascular risk].
    Orvosi hetilap, 2008, Jul-13, Volume: 149, Issue:28

    Topics: Antioxidants; Atherosclerosis; Carcinoma, Hepatocellular; Cardiovascular Diseases; Cytokines; Exercise; Fatty Acids, Nonesterified; Fatty Liver; Feeding Behavior; Humans; Insulin Resistance; Life Style; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Metabolic Syndrome; Obesity; Triglycerides; Ursodeoxycholic Acid

2008
Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
    Wiener medizinische Wochenschrift (1946), 2008, Volume: 158, Issue:19-20

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Bile; Bile Acids and Salts; Bile Canaliculi; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Cholangiocarcinoma; Cholangitis, Sclerosing; Cholestasis, Intrahepatic; Cholic Acids; Disease Models, Animal; Humans; Liver Neoplasms; Mice; Mice, Knockout; Mutation; Norsteroids; Ursodeoxycholic Acid

2008
Management of autoimmune liver disease.
    Minerva gastroenterologica e dietologica, 2009, Volume: 55, Issue:2

    Topics: Autoantibodies; Azathioprine; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Cholagogues and Choleretics; Cholangiocarcinoma; Clinical Trials as Topic; Drug Therapy, Combination; Evidence-Based Medicine; Glucocorticoids; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Ursodeoxycholic Acid

2009
Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode.
    International journal of molecular sciences, 2012, Volume: 13, Issue:7

    Topics: Animals; Carcinoma, Hepatocellular; Cholagogues and Choleretics; Coenzyme A; Cyclic AMP; DNA Repair; Humans; Liver Cirrhosis, Biliary; Liver Neoplasms; Liver Regeneration; Tumor Suppressor Protein p53; Ursodeoxycholic Acid

2012
[Clinical aspects of type-C cirrhosis of liver--diagnosis, clinical course, treatment and prognosis].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 7, Issue:Pt 1

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cysteine; Disease Progression; Drug Combinations; Drug Therapy, Combination; Fibrosis; Glycine; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Liver Neoplasms; Oleanolic Acid; Prognosis; Ribavirin; Risk; Ursodeoxycholic Acid

2004
Treatment strategies for chronic hepatitis C virus infection.
    Journal of gastroenterology, 2000, Volume: 35, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Carcinoma, Hepatocellular; Drugs, Chinese Herbal; Glycyrrhizic Acid; Hepatitis C, Chronic; Humans; Interferons; Iron Overload; Liver Neoplasms; Ribavirin; Treatment Outcome; Ursodeoxycholic Acid

2000
[Prevention of development of hepatocellular carcinoma from HCV-associated liver cirrhosis by multi-agents therapy including stronger-neo-minophagen C].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 6

    Topics: Anti-Inflammatory Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Cysteine; Drug Combinations; Drug Therapy, Combination; Drugs, Chinese Herbal; Glycine; Glycyrrhetinic Acid; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Risk; Treatment Outcome; Ursodeoxycholic Acid

2001

Trials

2 trial(s) available for ursodeoxycholic acid and Carcinoma, Hepatocellular

ArticleYear
Incidence of hepatocellular carcinoma reduced by phlebotomy treatment in patients with chronic hepatitis C.
    Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:2

    Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Carcinoma, Hepatocellular; Female; Glycyrrhizic Acid; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Phlebotomy; Platelet Count; Ursodeoxycholic Acid

2015
Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.
    Hepatology (Baltimore, Md.), 2013, Volume: 57, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Bezafibrate; Carcinoma, Hepatocellular; Cell Line, Tumor; Cholagogues and Choleretics; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Female; Humans; Lipids; Liver; Liver Cirrhosis, Biliary; Liver Neoplasms; Male; Middle Aged; PPAR alpha; Pregnane X Receptor; Receptors, Steroid; Treatment Failure; Treatment Outcome; Ursodeoxycholic Acid

2013

Other Studies

36 other study(ies) available for ursodeoxycholic acid and Carcinoma, Hepatocellular

ArticleYear
Bile acid inhibition of P-glycoprotein-mediated transport in multidrug-resistant cells and rat liver canalicular membrane vesicles.
    Hepatology (Baltimore, Md.), 1994, Volume: 20, Issue:1 Pt 1

    Topics: Animals; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bile Acids and Salts; Bile Canaliculi; Biological Transport; Carcinoma, Hepatocellular; Carrier Proteins; Cell Membrane; Daunorubicin; Depression, Chemical; Doxorubicin; Drug Resistance; Liver Neoplasms; Male; Membrane Glycoproteins; Rats; Rats, Sprague-Dawley; Rhodamine 123; Rhodamines; Tumor Cells, Cultured

1994
Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane.
    Hepatology (Baltimore, Md.), 2003, Volume: 38, Issue:2

    Topics: Adenosine Triphosphate; Amino Acid Sequence; Animals; Antibodies; Carcinoma, Hepatocellular; Cell Polarity; Cholagogues and Choleretics; Cricetinae; Fibroblasts; Gene Expression; Glutathione; Hepatocytes; Humans; Liver Neoplasms; Male; Mice; Molecular Sequence Data; Multidrug Resistance-Associated Proteins; Rats; Taurocholic Acid; Transfection; Transport Vesicles; Tritium

2003
Design, synthesis, and antihepatocellular carcinoma activity of nitric oxide releasing derivatives of oleanolic acid.
    Journal of medicinal chemistry, 2008, Aug-14, Volume: 51, Issue:15

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line; Drug Design; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Molecular Structure; Nitric Oxide; Oleanolic Acid

2008
Ethnicity, disease severity, and survival in Canadian patients with primary biliary cholangitis.
    Hepatology (Baltimore, Md.), 2022, Volume: 76, Issue:2

    Topics: Canada; Carcinoma, Hepatocellular; Cholangitis; Ethnicity; Humans; Liver Cirrhosis, Biliary; Liver Neoplasms; Quality of Life; Severity of Illness Index; Treatment Outcome; Ursodeoxycholic Acid

2022
Anticancer Activity and Molecular Mechanisms of an Ursodeoxycholic Acid Methyl Ester-Dihydroartemisinin Hybrid via a Triazole Linkage in Hepatocellular Carcinoma Cells.
    Molecules (Basel, Switzerland), 2023, Mar-03, Volume: 28, Issue:5

    Topics: Apoptosis; Artemether; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms; Tandem Mass Spectrometry; Ursodeoxycholic Acid

2023
Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis.
    The American journal of gastroenterology, 2021, 09-01, Volume: 116, Issue:9

    Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Cholagogues and Choleretics; Female; Humans; Liver Cirrhosis, Biliary; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Ursodeoxycholic Acid

2021
Omega-3 Polyunsaturated Fatty Acid: A Pharmaco-Nutraceutical Approach to Improve the Responsiveness to Ursodeoxycholic Acid.
    Nutrients, 2021, Jul-29, Volume: 13, Issue:8

    Topics: Apoptosis; Autoimmune Diseases; Bile Acids and Salts; Carcinoma, Hepatocellular; Caspase 3; Cholangitis, Sclerosing; Cholestanetriol 26-Monooxygenase; Cholestasis; Cholesterol 7-alpha-Hydroxylase; Dietary Supplements; Down-Regulation; Drug Therapy, Combination; Endoplasmic Reticulum Stress; Fatty Acids, Omega-3; Gene Expression; Hep G2 Cells; Humans; Inflammation; Liver; Liver Cirrhosis, Biliary; Liver Diseases; THP-1 Cells; Ursodeoxycholic Acid

2021
Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
    The American journal of gastroenterology, 2018, Volume: 113, Issue:1

    Topics: Alkaline Phosphatase; Bezafibrate; Carcinoma, Hepatocellular; Cholagogues and Choleretics; Disease Progression; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Humans; Hypolipidemic Agents; Jaundice; Liver Cirrhosis, Biliary; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Prognosis; Pruritus; Ursodeoxycholic Acid; Visual Analog Scale

2018
Synergistic effect of ursodeoxycholic acid on the antitumor activity of sorafenib in hepatocellular carcinoma cells via modulation of STAT3 and ERK.
    International journal of molecular medicine, 2018, Volume: 42, Issue:5

    Topics: Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Survival; Extracellular Signal-Regulated MAP Kinases; Hep G2 Cells; Humans; Liver Neoplasms; Phosphorylation; Reactive Oxygen Species; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Ursodeoxycholic Acid

2018
Effects of hepatocellular carcinoma on the survival of patients with primary biliary cirrhosis in the era of ursodeoxycholic acid therapy.
    Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:14

    Topics: Carcinoma, Hepatocellular; Cholagogues and Choleretics; Humans; Liver Cirrhosis, Biliary; Liver Neoplasms; Survival Rate; Treatment Outcome; Ursodeoxycholic Acid

2013
Ursodeoxycholic acid induces apoptosis of hepatocellular carcinoma cells in vitro.
    Journal of digestive diseases, 2014, Volume: 15, Issue:12

    Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Caspase 3; Cell Cycle; Cell Survival; Cholagogues and Choleretics; Gene Expression; Hep G2 Cells; Humans; In Vitro Techniques; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Mitochondrial Proteins; Neoplasm Proteins; Ursodeoxycholic Acid

2014
U12, a UDCA derivative, acts as an anti-hepatoma drug lead and inhibits the mTOR/S6K1 and cyclin/CDK complex pathways.
    PloS one, 2014, Volume: 9, Issue:12

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin-Dependent Kinases; Cyclins; Disease Models, Animal; Humans; Liver Neoplasms; Male; Mice; Protein Binding; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Burden; Ursodeoxycholic Acid; Xenograft Model Antitumor Assays

2014
Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study.
    Gut, 2016, Volume: 65, Issue:2

    Topics: Aspartate Aminotransferases; Carcinoma, Hepatocellular; Europe; Female; Humans; Kaplan-Meier Estimate; Liver Cirrhosis, Biliary; Liver Neoplasms; Logistic Models; Male; North America; Proportional Hazards Models; Risk; Risk Factors; Sex Factors; Thrombocytopenia; Ursodeoxycholic Acid

2016
[Ursodeoxycholic acid induced apoptosis of human hepatoma cells HepG2 and SMMC-7721 bymitochondrial-mediated pathway].
    Zhonghua yi xue za zhi, 2014, Dec-02, Volume: 94, Issue:44

    Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Liver Neoplasms; Mitochondria; Up-Regulation; Ursodeoxycholic Acid

2014
Ursodeoxycholic acid induces apoptosis in hepatocellular carcinoma xenografts in mice.
    World journal of gastroenterology, 2015, Sep-28, Volume: 21, Issue:36

    Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Time Factors; Tumor Burden; Ursodeoxycholic Acid; Xenograft Model Antitumor Assays

2015
Oral Medications Enhance Adherence to Surveillance for Hepatocellular Carcinoma and Survival in Chronic Hepatitis B Patients.
    PloS one, 2017, Volume: 12, Issue:1

    Topics: Antioxidants; Antiviral Agents; Carcinoma, Hepatocellular; Cholagogues and Choleretics; Early Detection of Cancer; Female; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Patient Compliance; Prognosis; Retrospective Studies; Silymarin; Ursodeoxycholic Acid

2017
Management of autoimmune and cholestatic liver disorders.
    Clinics in liver disease, 2009, Volume: 13, Issue:2

    Topics: Anti-Inflammatory Agents; Azathioprine; Carcinoma, Hepatocellular; Cholagogues and Choleretics; Cholangitis, Sclerosing; Chronic Disease; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Liver Cirrhosis, Biliary; Liver Neoplasms; Liver Transplantation; Practice Guidelines as Topic; Prednisone; Ursodeoxycholic Acid

2009
Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma.
    International journal of cancer, 2010, Apr-01, Volume: 126, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Caspase 8; Cholagogues and Choleretics; Electrophoretic Mobility Shift Assay; Hep G2 Cells; HT29 Cells; Humans; L-Lactate Dehydrogenase; Liver Neoplasms; Necrosis; Organoplatinum Compounds; Oxaliplatin; Reactive Oxygen Species; RNA, Small Interfering; Tumor Suppressor Protein p53; Ursodeoxycholic Acid

2010
Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study.
    European journal of gastroenterology & hepatology, 2010, Volume: 22, Issue:7

    Topics: Adolescent; Adult; Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Cholangiocarcinoma; Cholangitis, Sclerosing; Cohort Studies; Colorectal Neoplasms; Female; France; Gallbladder Neoplasms; Humans; Incidence; Liver Failure; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Prognosis; Prospective Studies; Treatment Outcome; Ursodeoxycholic Acid; Young Adult

2010
A concentration-dependent effect of ursodeoxycholate on apoptosis and caspases activities of HepG2 hepatocellular carcinoma cells.
    European journal of pharmacology, 2010, Aug-25, Volume: 640, Issue:1-3

    Topics: Annexin A5; Apoptosis; Carcinoma, Hepatocellular; Caspases; Cell Proliferation; DNA Fragmentation; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Ligands; Organ Specificity; Signal Transduction; Tumor Necrosis Factor-alpha; Ursodeoxycholic Acid

2010
Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
    Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:5

    Topics: Animals; Apoptosis; Bile; Bile Acids and Salts; Carcinoma, Hepatocellular; Cholangitis; Cholestasis; Chromatography, Gas; Hepatoblastoma; Humans; Liver; Liver Diseases; Liver Neoplasms; Male; Mice; Rats; Rats, Sprague-Dawley; Taurine; Taurolithocholic Acid; Ursodeoxycholic Acid

2010
Mitochondrial genome depletion dysregulates bile acid- and paracetamol-induced expression of the transporters Mdr1, Mrp1 and Mrp4 in liver cells.
    British journal of pharmacology, 2011, Volume: 162, Issue:8

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Hepatocellular; Cell Line, Tumor; Gene Expression Regulation; Genome, Mitochondrial; Glycochenodeoxycholic Acid; Liver; Mice; Multidrug Resistance-Associated Proteins; NF-E2-Related Factor 2; Reactive Oxygen Species; RNA, Ribosomal; Ursodeoxycholic Acid

2011
Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid.
    European journal of gastroenterology & hepatology, 2010, Volume: 22, Issue:12

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Cause of Death; Cholagogues and Choleretics; Female; Humans; Incidence; Kaplan-Meier Estimate; Liver Cirrhosis, Biliary; Liver Neoplasms; Male; Mass Screening; Middle Aged; Netherlands; Patient Selection; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Failure; Ursodeoxycholic Acid

2010
Ursodeoxycholic acid-induced inhibition of DLC1 protein degradation leads to suppression of hepatocellular carcinoma cell growth.
    Oncology reports, 2011, Volume: 25, Issue:6

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene Expression; GTPase-Activating Proteins; Humans; Immunoprecipitation; Liver Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Proteins; Ursodeoxycholic Acid

2011
Risk factors for hepatocellular carcinoma in Japanese patients with autoimmune hepatitis type 1.
    Journal of gastroenterology, 2012, Volume: 47, Issue:5

    Topics: Aged; Alanine Transaminase; Azathioprine; Biomarkers; Carcinoma, Hepatocellular; Cholagogues and Choleretics; Drug Therapy, Combination; Female; Glucocorticoids; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Japan; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prednisolone; Retrospective Studies; Risk Factors; Treatment Outcome; Ursodeoxycholic Acid

2012
The effect of ursodeoxycholic acid on the survivin in thapsigargin-induced apoptosis.
    Cancer letters, 2003, Feb-28, Volume: 191, Issue:1

    Topics: Apoptosis; Calpain; Carcinoma, Hepatocellular; Caspase 12; Caspases; DNA Fragmentation; Endoplasmic Reticulum; Enzyme Activation; Genes, bcl-2; Humans; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Microtubule-Associated Proteins; Neoplasm Proteins; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Stress, Physiological; Survivin; Thapsigargin; Tumor Cells, Cultured; Ursodeoxycholic Acid

2003
Evidence for dual effects of DNA-reactive bile acid derivatives (Bamets) on hepatitis B virus life cycle in an in vitro replicative system.
    Antiviral chemistry & chemotherapy, 2002, Volume: 13, Issue:6

    Topics: Carcinoma, Hepatocellular; Cisplatin; Culture Media, Conditioned; DNA, Circular; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Liver Neoplasms; Organoplatinum Compounds; Structure-Activity Relationship; Transfection; Tumor Cells, Cultured; Ursodeoxycholic Acid; Viral Proteins; Virion; Virus Replication

2002
Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2005, Volume: 14, Issue:1

    Topics: Alanine Transaminase; Analysis of Variance; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Cholagogues and Choleretics; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Glycyrrhizic Acid; Hepacivirus; Hepatitis C; Humans; Incidence; Inflammation; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Middle Aged; Risk Factors; Treatment Outcome; Ursodeoxycholic Acid

2005
Suppressive effect of ursodeoxycholic acid on type IIA phospholipase A2 expression in HepG2 cells.
    Hepatology (Baltimore, Md.), 2005, Volume: 41, Issue:4

    Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cytokines; Dose-Response Relationship, Drug; Humans; Inflammation Mediators; Isoenzymes; Liver Neoplasms; Phospholipases A; Phospholipases A2; Receptors, Glucocorticoid; Receptors, Interleukin-6; Signal Transduction; Transcription, Genetic; Ursodeoxycholic Acid

2005
Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis.
    Alimentary pharmacology & therapeutics, 2006, Oct-15, Volume: 24, Issue:8

    Topics: Adolescent; Adult; Aged; Alanine Transaminase; Anti-Inflammatory Agents; Azathioprine; Carcinoma, Hepatocellular; Cholagogues and Choleretics; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prednisolone; Prospective Studies; Recurrence; Treatment Outcome; Ursodeoxycholic Acid

2006
Mechanism of apoptotic effects induced selectively by ursodeoxycholic acid on human hepatoma cell lines.
    World journal of gastroenterology, 2007, Mar-21, Volume: 13, Issue:11

    Topics: Apoptosis; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Proliferation; Cholagogues and Choleretics; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA Fragmentation; Gene Expression Regulation, Neoplastic; Humans; Liver; Liver Neoplasms; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53; Ursodeoxycholic Acid

2007
Effects of ursodeoxycholic acid and chenodeoxycholic acid on major histocompatibility complex class I gene expression.
    Journal of gastroenterology, 1996, Volume: 31, Issue:1

    Topics: Blotting, Northern; Carcinoma, Hepatocellular; Chenodeoxycholic Acid; Gene Expression; Histocompatibility Antigens Class I; Humans; Liver Neoplasms; RNA, Messenger; Tumor Cells, Cultured; Ursodeoxycholic Acid

1996
Regulation of alkaline phosphatase gene expression in human hepatoma cells by bile acids.
    Journal of gastroenterology and hepatology, 1998, Volume: 13, Issue:6

    Topics: Alkaline Phosphatase; Bile Acids and Salts; Carcinoma, Hepatocellular; Chenodeoxycholic Acid; Cholic Acid; Dose-Response Relationship, Drug; Gene Expression; Humans; Liver Neoplasms; RNA, Messenger; Tumor Cells, Cultured; Ursodeoxycholic Acid

1998
Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors.
    The Journal of pharmacology and experimental therapeutics, 2001, Volume: 297, Issue:3

    Topics: Animals; Antineoplastic Agents; Bone Marrow; Carcinoma, Hepatocellular; Cisplatin; Disease Models, Animal; Drug Evaluation, Preclinical; Injections, Intraperitoneal; Kidney; Kidney Function Tests; Liver; Liver Neoplasms, Experimental; Male; Mice; Mice, Nude; Myocardium; Neoplasm Transplantation; Neural Conduction; Organoplatinum Compounds; Platinum; Rats; Rats, Wistar; Sciatic Nerve; Survival Rate; Tissue Distribution; Tumor Cells, Cultured; Ursodeoxycholic Acid

2001
Geranylgeraniol, an intermediate product in mevalonate pathway, induces apoptotic cell death in human hepatoma cells: death receptor-independent activation of caspase-8 with down-regulation of Bcl-xL expression.
    Japanese journal of cancer research : Gann, 2001, Volume: 92, Issue:9

    Topics: Apoptosis; bcl-X Protein; Carcinoma, Hepatocellular; Caspase 3; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; Cysteine Proteinase Inhibitors; Diterpenes; Enzyme Activation; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mevalonic Acid; Neoplasm Proteins; Oligopeptides; Proteins; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Tumor Cells, Cultured; Ursodeoxycholic Acid; X-Linked Inhibitor of Apoptosis Protein

2001
Ursodeoxycholic acid-dependent activation of the glucocorticoid receptor.
    Biochemical and biophysical research communications, 1992, Oct-30, Volume: 188, Issue:2

    Topics: Animals; Base Sequence; Carcinoma, Hepatocellular; Cell Nucleus; Chloramphenicol O-Acetyltransferase; CHO Cells; Cricetinae; Cytosol; Humans; Liver Neoplasms; Molecular Sequence Data; Oligonucleotide Probes; Plasmids; Promoter Regions, Genetic; Receptors, Glucocorticoid; Recombinant Fusion Proteins; Signal Transduction; Transfection; Tumor Cells, Cultured; Tyrosine Transaminase; Ursodeoxycholic Acid

1992